IMMvention Therapeutix To Collaborate With Novo Nordisk On Oral Therapies For Sickle Cell, Other Chronic Diseases

IMMvention Therapeutix, Inc., an innovative biotechnology company based in Durham, has announced a strategic collaboration with Novo Nordisk A/S. This partnership aims to co-develop oral therapies for sickle cell disease (SCD) and other chronic conditions, which leverages IMMvention's cutting-edge research and development capabilities.

Central to this collaboration are IMMvention's investigational small-molecule Bach1 inhibitors. Bach1 is considered a crucial regulator of cellular responses, oxidative stress, and inflammation across various disease states, positioning it as a promising therapeutic target. IMMvention's Bach1 inhibitors, currently in preclinical development, are designed to be administered orally. These inhibitors have shown the potential to increase fetal hemoglobin levels, which is believed to mitigate the pathological effects of SCD.

Access the full article to learn more.